Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies
Fred R. Hirsch
, Keith M. Kerr
, Paul A. Bunn
, Edward S. Kim
, Coleman Obasaju
, Maurice Pérol
, Philip Bonomi
, Jeffrey D. Bradley
, David Gandara
, James R. Jett
, Corey J. Langer
, Ronald B. Natale
, Silvia Novello
, Luis Paz-Ares
, Suresh S. Ramalingam
, Martin Reck
, Craig H. Reynolds
, Egbert F. Smit
, Mark A. Socinski
, David R. Spigel
Thomas E. Stinchcombe, Johan F. Vansteenkiste, Heather Wakelee, Nick Thatcher
Show 4 others
Show less
Research output
:
Contribution to journal
›
Review article
›
peer-review
18
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Current Therapies
100%
Squamous Cell Lung Cancer
100%
Molecular Biomarkers
100%
Future Therapies
100%
Biomarker Testing
100%
Immune Markers
100%
Cancer Effects
100%
Non-small Cell Lung Cancer (NSCLC)
50%
Optimal Treatment
25%
Patient Demographics
25%
Current Treatment
25%
Radiotherapy
25%
Advanced Stage
25%
Targeted Agents
25%
Treatment Choice
25%
Rapidly Evolving
25%
Chemotherapy Agents
25%
Treatment Landscape
25%
Immunotherapy Agents
25%
Medicine and Dentistry
Biological Marker
100%
Squamous Cell Lung Carcinoma
100%
Non Small Cell Lung Cancer
50%
Immunotherapy
25%
Patient Population
25%
Radiation Therapy
25%
Immunology and Microbiology
Squamous Cell
100%
Immunotherapy
25%